Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $202.6 million.

  • Enanta Pharmaceuticals' Total Non-Current Liabilities fell 1434.88% to $202.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $202.6 million, marking a year-over-year decrease of 1434.88%. This contributed to the annual value of $215.8 million for FY2025, which is 1286.39% down from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Total Non-Current Liabilities is $202.6 million, which was down 1434.88% from $215.8 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $256.9 million in Q2 2023 and a low of $30.7 million during Q1 2021
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $209.2 million (2025), whereas its average is $149.8 million.
  • In the last 5 years, Enanta Pharmaceuticals' Total Non-Current Liabilities crashed by 1638.73% in 2022 and then skyrocketed by 44957.01% in 2023.
  • Enanta Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $55.4 million in 2021, then fell by 16.39% to $46.3 million in 2022, then soared by 409.83% to $236.0 million in 2023, then grew by 0.26% to $236.6 million in 2024, then decreased by 14.35% to $202.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $202.6 million for Q4 2025, versus $215.8 million for Q3 2025 and $221.5 million for Q2 2025.